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brain damage in humans. There was some support from the animal literature, but few human studies had been
conducted where the findings could not be explained by methodological or other confounding factors. Recent
evidence for gross morphological, connectivity and microstructural changes has now emerged that warrants
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Does cannabis cause lasting
brain damage?
Nadia Solowij, Murat Yücel, Valentina Lorenzetti and Dan Lubman

Until recently, it was possible to state with some confidence that there was no evidence of cannabis-related
brain damage in humans. There was some support from
the animal literature, but few human studies had been
conducted where the findings could not be explained
by methodological or other confounding factors.
Recent evidence for gross morphological, connectivity and microstructural changes has now emerged that
warrants further consideration. If cannabis were found
to alter the structural integrity of the brain, then this
may assist us to understand the mechanisms by which
cannabis triggers psychotic symptoms or overt psychosis in vulnerable individuals.

Evidence from animal studies
Cannabinoids, either endogenous or exogenous, possess both neuroprotective and neurotoxic properties (Sarne and Mechoulam, 2005; Kano et al., 2009).
Cannabinoid-receptor activation induces morphological changes to neurons, such as inhibition of new
synapse formation (Kano et al., 2009), and at crucial
neurodevelopmental stages (prenatal and adolescent),
exposure to cannabinoids impacts on neural cell survival and maturation (Chapters 6, 7) (Downer and
Campbell, 2010). The role of different cannabinoids in
controlling neural-cell survival or death is a complex
issue that is influenced by the dose, duration of exposure and route of administration, but also the neuralcell type and its stage of differentiation (Downer and
Campbell, 2010). Contradictory hypotheses circulate
regarding the doses of Δ9-tetrahydrocannabinol (THC)
that may be neurotoxic or neuroprotective. Some suggest that single high doses of THC are neuroprotective within a limited timeframe, but that low doses are
neurotoxic and, with chronic exposure, induce neuronal death (Sarne and Keren, 2004; Tselnicker et al,
2007; Sarne and Mechoulam, 2005). However, large

doses of THC applied directly to cultured hippocampal neurons, and both high and low doses to cultured
cortical neurons, have been shown to cause cell death
or significant neurotoxic changes (eg. shrinkage of
cell bodies and DNA-strand breaks) characteristic of
neuronal apoptosis (Chan et al., 1998; Campbell, 2001;
Downer et al., 2001). Indeed, even a single administration of an ultra-low dose of THC (0.001–0.002 mg/
kg) has been shown to result in long-term cognitive
impairment (in spatial learning, strategy and working
memory) in mice. These defecits persisted for at least
5 months post-injection and were associated with activation of extracellular-regulated kinase (ERK) in the
cerebellum and hippocampus (Tselnicker et al., 2007;
Amal et al., 2010). The authors suggested that low THC
concentration is the main determinant of long-lasting
neuronal effects following chronic exposure to cannabinoids, due to their slow clearance and accumulation (Amal et al., 2010).
A study of cannabinoid application in vitro showed
that THC appears to accumulate primarily in neurons
and that transformation to its metabolite, THC-COOH,
depends on the presence of glia (Monnet-Tschudi et al.,
2008). The authors suggested that the adverse effects of
cannabinoids on the brain may occur through a combination of pathways involving cannabinoid receptor
activation, accumulation of cannabinoids and their
metabolites and upregulation of neuroinflammatory
cytokines. Given the dependence on glia for metabolism of THC, if white-matter aberrations develop
in cannabis users (as discussed further below), more
THC could potentially accumulate in neurons, causing
toxicity.
Studies of chronic cannabinoid administration to
animals have demonstrated cognitive impairment associated with specific neurochemical, transmission and cell
firing alterations, particularly in the hippocampus, but
also the prefrontal cortex (PFC), similar to impairment

Marijuana and Madness, Second Edition, ed. David Castle, Robin M. Murray and Deepak Cyril D’Souza. Published by
Cambridge University Press. © Cambridge University Press 2012.
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induced by lesions or transient inactivation (Egerton
et al., 2006). Chronic administration of THC to rats and
primates has been shown to result in dose-dependent
neurotoxic changes in brain regions that are rich in cannabinoid receptors. Specifically, THC-induced neurotoxic effects are prominent within the hippocampus
(Heath et al., 1980; Scallet et al., 1987; Landfield et al.,
1988; Chan et al., 1998; Lawston et al., 2000), amygdala (Heath et al., 1980), septum (Harper et al., 1977;
Myers and Heath., 1979) and cerebral cortex (Harper
et al., 1977; Downer et al., 2001). These neurotoxic
effects include shrinkage of neural cell nuclei and bodies
(Heath et al., 1980; Scallet et al., 1987) and reductions in
pyramidal cell density (Lawston et al., 2000), dendritic
length (Landfield et al., 1988) and number of synapses
(Heath et al., 1980). Some of these studies have emulated
chronic-use patterns seen in humans: for example, in
the study by Landfield and colleagues (1988) THC was
administered to rats five times a week for 8 months, representing approximately 30% of the rats’ lifespan.
Cannabis use in humans typically commences
during adolescence and young adulthood, a crucial period of neurodevelopment (see Chapter 7).
Neuromaturational changes primarily occur within
PFC and limbic circuits, and include progressive and
regressive changes such as myelination and synaptic
pruning, neurogenesis and apoptosis, axonal growth
and sprouting, dendritic arborization and retraction,
synaptogenesis and synapse elimination, alongside
the maturation of multiple neurotransmitter systems
(Schneider, 2008; Realini et al., 2009). The endocannabinoid (eCB) system (ECS) is crucially involved in
these developmental processes (Harkany et al., 2008;
Schneider, 2008; Realini et al., 2009) that are thought
to be essential for the acquisition of adult cognition,
decision-making and social behaviors. As such, exposure to THC during adolescence may perturb neurodevelopmental processes with potential long lasting
consequences.
As discussed in detail in Chapter 7, a number of
studies have examined the impact of THC administration during adolescence on the adult brain. For
instance, Rubino and colleagues (2009a) administered
THC twice daily to adolescent rats for 10 days and then
left them undisturbed until adulthood, at which point
they assessed learning and memory capacities, as well
as their underlying neural substrates. Deficits in spatial memory were evident in the pretreated rats and
were accompanied by, and correlated with, significantly
lower total dendritic length and number, reduced spine
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density and decreases in astroglial markers, protein
expression and N-methyl-d-aspartate receptor levels
within the hippocampus. Thus, adolescent exposure to
THC resulted in long-lasting alterations to the structural and functional plasticity of both neurons and glia,
with a reduction in synaptic contacts and/or less efficient synaptic connections throughout the hippocampus. In other studies, these authors found significant
gender-related THC neurotoxic effects, demonstrating
that CB1 receptor density and G-protein coupling were
significantly reduced in the amygdala, ventral tegmental
area and nucleus accumbens in female rats, but only in
the amygdala and hippocampus of male rats, accompanied by different behavioral profiles (Rubino et al., 2008).
Further, spatial working memory impairment was similar between genders but was underpinned by hippocampal alterations in males, in contrast to PFC alterations
in females (Rubino et al., 2009b). This work supports
a growing literature demonstrating sex differences in
adulthood in animals chronically administered THC
during adolescence, as well as alterations within circuits
underlying emotional processing (Realini et al., 2009).
There is also growing evidence of differential
responses to cannabis during adolescence compared with adulthood. Quinn et al. (2008) found that
repeated exposure to THC was less behaviorally aversive for adolescent compared with adult rats, but caused
greater persistent memory deficits and hippocampal
structural and functional alterations. Altered protein
expression in the hippocampus was observed in both
adult and adolescent rats, but adolescent rats showed
a greater number of altered proteins related to oxidative stress, mitochondrial and metabolic function, cell
proliferation and repair, and cytoskeletal structure
and signaling. Further recent research on neurotransmitter system functionality and cannabinoid receptor
changes following chronic exposure to cannabinoids
suggests that the adolescent brain does not compensate for the biological changes in response to cannabis
exposure in the same way as the adult brain (Dalton
and Zavitsanou, 2010; Zavitsanou et al., 2010). The ECS
also appears to be altered by exposure to THC during
early, middle and late adolescence (Ellgren et al., 2008).
In a rat study, intermittent exposure to THC (a pattern
of use common among teenagers) was found to reverse
the normal proportional ratio of eCBs (anandamide
and 2-arachidonoyl glycerol [2-AG]) in the PFC and
nucleus accumbens. These studies support the notion
that THC effects on neural integrity may depend on
different developmental stages of exposure.
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Thus, evidence from preclinical research has identified neurotoxic, morphological and microstructural
alterations to the brain in vitro and, when animals are
acutely or chronically exposed to cannabinoids, at
doses relevant to human use. With discrepant results
concerning the neurotoxicity of low and high doses,
and accumulation of cannabinoids, further research
must reconcile dose-effects in vitro versus in vivo, and
consider the various cannabinoids that human users
expose themselves to. Some of these have been shown
to have differential properties and opposing effects in
humans (eg. THC versus cannabidiol; see Chapter 1).
As such, animal research could examine each of these
in isolation and in combination, and further elucidate
their impact on the developing brain.

Evidence from human studies
Adult chronic cannabis users
Findings of persistent alteration of brain function or
cognitive impairment in human cannabis users (as
reviewed in Chapter 8), together with the animal work
discussed above, support the notion that long-term
cannabis use may result in morphological alterations
of brain structures that subserve attention, learning,
memory, executive functions and emotional processes
(such as the prefrontal and temporal cortices). To date,
findings from structural neuroimaging studies of longterm cannabis users have been contradictory, with
evidence for both the presence and absence of morphological changes in specific brain regions (DeLisi, 2008;
Solowij et al., 2009; Lorenzetti et al., 2010; MartinSantos et al., 2010). However, a number of variables,
such as demographic, clinical, genetic and drug-use
factors are likely to mediate the relationship between
cannabis use and brain structural alterations.
A recent review (Lorenzetti et al., 2010) identified
only 13 structural neuroimaging studies where the primary substance used was cannabis and major psychopathologies were excluded. The main imaging modality
utilized was magnetic resonance imaging (MRI) (eight
studies), with three studies employing computed
tomography (CT) and two early studies using pneumo-encephalography and echo-encephalography,
respectively. The MRI studies used either a region-ofinterest approach (six studies) or voxel-based morphometry (VBM; two studies). No significant differences
were found in any of the studies on global measures
of brain volume. More specific regional brain analyses

demonstrated evidence of structural brain abnormalities, but these were not consistent across studies.
Six studies reported specific regional structural
alterations in regular cannabis users (Campbell et al.,
1971; Block et al., 2000; Wilson et al., 2000; Matochik
et al., 2005; Medina et al., 2007b; Yücel et al., 2008), while
the remaining seven studies found no significant volumetric differences between users and controls (Stefanis,
1976; Co et al., 1977; Kuehnle et al., 1977; Hannerz
and Hindmarsh, 1983; Jager et al., 2007; Medina et al.,
2007a; Tzilos et al., 2005). Alterations in hippocampal
or parahippocampal volumes were the most consistently reported findings, but the nature of the findings
were still mixed. Hippocampal volumes in cannabis
users were found to be smaller (Matochik et al., 2005;
Yücel et al., 2008), larger (Medina et al., 2007b), or no
different to controls (Block et al., 2000; Wilson et al.,
2000; Medina et al., 2007a). Of three studies that examined parahippocampal volume, two reported no change
(Jager et al., 2007; Tzilos et al., 2005), while one found
an alteration in grey and white matter composition
(Matochik et al., 2005). Two studies examined amygdala
volumes, with one reporting reduced volume (Yücel
et al., 2008) and the other no change (Wilson et al.,
2000). Finally, there were a number of brain regions that
were investigated only within a single study, with significant between-group differences found for the precentral gyrus, thalamus, parietal lobule, fusiform gyrus,
lentiform nucleus and pons (Matochik et al., 2005), but
not for the cerebellum (Block et al., 2000). While few
studies have specifically examined white-matter volume, we recently identified significant cerebellar white
matter reduction in adult long-term very heavy cannabis users (Solowij et al., 2011).
Dose and duration of cannabis exposure may differentiate between those studies that did or did not find
volumetric differences between users and controls. For
example, in our study (Yücel et al., 2008) the cannabis
users had a similar exposure to that of Landfield et al.’s
(1988) rodent study (cited above). Both of these studies
found significant dose-related reductions in hippocampal volume. The cannabis users within our study had
the most extensive exposure to cannabis of all the studies of human cannabis users (near daily use for a mean
19.7 years, range 10–32 years), and the most striking
findings. We reported a 12% reduction bilaterally in
hippocampal volumes, as well as an approximate 7%
reduction in bilateral amygdala volumes (Yücel et al.,
2008), and a 24% reduction in cerebellar white matter
(Solowij et al., 2011). The reduction of left hippocampal
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volume was of a similar magnitude to that observed in
schizophrenia, was dose-related and was associated
with subclinical psychotic symptoms, even though our
sample was carefully screened for DSM-IV psychotic
disorders.
One other study with a similar mean duration of
use (mean 22.6 years, range 12–33 years) to the sample in our study, reported no brain alterations, but the
minimum duration of daily use in that sample was only
one year (Tzilos et al., 2005). In contrast, the minimum
duration of near daily use in our study was 10 years. A
further key difference between the Tzilos et al. (2005)
study and ours was in the estimated episodes of use,
and hence the cumulative dose of exposure to cannabis.
Tzilos et al.’s sample reported an average of 20 100 lifetime episodes of use. Our sample had an average 62 000
estimated episodes of use over the lifetime. Thus, despite a similar mean duration of use, our cannabis users
used more than three times as much cannabis, which
may be the crucial factor in explaining our finding of a
dose–response relationship between hippocampal volume and cumulative cannabis use. In addition, Tzilos
et al.. (2005) acquired their images at a lower field
strength and with a coarser spatial resolution (1.5 T
with 3-mm-thick slices vs. 3 T with 1-mm-thick slices
in our study), an important consideration given the
small size and boundary definition of the brain structures investigated. Moreover, the region of interest
measured in their study was less specific to the hippocampus relative to ours because they also included the
parahippocampal gyrus (ours was restricted to the
hippocampus itself using well-defined boundaries).
A general trend for an inverse relationship between
indices of cannabis use and hippocampal or parahippocampal volume appears to exist in other studies.
Aside from our own study, samples with greater cannabis exposure demonstrated reductions in hippocampal
or parahippocampal volumes (Matochik et al., 2005),
whereas samples with a lower quantity or frequency of
cannabis use exhibited no change (Block et al., 2000;
Wilson et al., 2000; Jager et al., 2007; Medina et al.,
2007a; Tzilos et al., 2005), or even volumetric increases
(Medina et al. 2007b). Studies of heavy cannabis users
(Matochik et al., 2005; Yücel et al., 2008) were more
likely to detect regional abnormalities than those of
lighter cannabis users. Greater brain alterations with an
earlier age of onset of cannabis use have been reported
in some studies (Wilson et al., 2000), but not others
(Matochik et al., 2005; Tzilos et al., 2005), but this aspect
of human cannabis use remains underinvestigated.
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Several recent studies have examined the integrity of white matter fiber tracts in cannabis users using
diffusion tensor imaging (DTI), including studies of
adolescent users (reported below). A pilot study in
ten heavy cannabis users demonstrated trends toward
both increased mean diffusivity and lower fractional
anisotropy in the anterior cingulate cortex (Gruber
and Yurgelun-Todd, 2005). Another study of heavy
users found significantly increased mean diffusivity in
the anterior region of the corpus callosum, where white
matter passes between the prefrontal lobes (Arnone
et al., 2008). The data suggest impaired structural integrity of the corpus callosum fiber tracts with prolonged
cannabis exposure, particularly as the authors reported
an association with duration of cannabis use within the
sample. White matter tractography investigations in
cannabis users are only at a preliminary stage of investigation and hold much promise for the future.
A post-mortem study of cannabinoid receptor density and integrity in human brains found that
the receptor becomes hypofunctional with chronic
cannabis use (Villares, 2007). Downregulation was
observed in the hippocampus, basal ganglia and mesencephalon of chronic users, and reduced binding levels were accompanied by parallel decreases in mRNA
levels. These findings suggest that the primary effect of
chronic exposure was on the CB1 receptor gene rather
than on the receptor protein. Evidence of diminished
neuronal and axonal integrity in the dorsolateral prefrontal cortex has been indicated by magnetic resonance spectroscopic markers of metabolism (NAA/tCr
ratio) (Hermann et al., 2007). Dose-related changes in
this study were also found in the anterior cingulate and
putamen/globus pallidum, but not in the hippocampus.
Acute and chronic exposure to cannabis in humans has
also been associated with reduced serum concentrations of neurotrophins, including nerve growth factor
(Angelucci et al., 2008) and brain derived neurotrophic
factor (BDNF) (D’Souza et al., 2009).
Thus, there is growing evidence for alterations to
the structural integrity of the brain as a result of chronic
cannabis exposure in adult users. This includes gross
structural anatomical studies of long term and heavy
users, as well as more refined studies of white matter
and connectivity, and neurotoxic markers in vivo.

Adolescent and young-adult cannabis users
An increasing number of studies have investigated
brain morphology in adolescent cannabis users or in
adults who started using cannabis at a young age. A
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study of adult users reported that early onset cannabis
users (before age 17 years) had smaller whole brain volumes, lower percent cortical grey matter, higher percent white matter and increased cerebral blood flow
compared with later onset users (Wilson et al., 2000).
The two studies by Medina and colleagues discussed
above were of adolescents, one reporting larger hippocampal volumes in users (Medina et al., 2007b), while the
other found no volumetric differences from controls
(Medina et al., 2007a). Medina et al. (2007a) also found
an association between whole brain white matter volume and depressive symptoms in young adult cannabis
users. While a DTI study of young adults who had at least
one year of daily or several times/week cannabis during
adolescence, found no evidence of pathological white
matter integrity differences between users and controls, it identified several regions of apparently greater
integrity among users (DeLisi et al., 2006). However, a
solid body of evidence for pathology in white matter
tracts within the corpus callosum and various frontotemporal, occipito-frontal and posterior connections
that develop during adolescence, has come from other
recent DTI studies of young adult (Arnone et al., 2008;
Allin et al., 2009) and adolescent (Ashtari et al., 2009;
Bava et al., 2009; Yücel et al., 2011) cannabis users, as
well as adolescents with substance use disorders (primarily cannabis) (Thatcher et al., 2010). Abnormalities
in this latter study were greater in females than in males.
The results from these studies overall suggest that cannabis use, particularly during adolescence, may affect
the trajectory of normal brain maturation resulting in
white matter aberrations, which may underlie compromised cognitive processing and may even underpin the
propensity for cannabis to cause psychosis (Allin et al.,
2009; Solowij et al., 2011).
Interestingly, Jacobus et al. (2009) reported greater
white matter integrity alterations in several brain
regions in adolescent binge drinkers than in adolescent
heavy cannabis users who were also binge drinkers. The
latter group differed from controls in three regions,
while alcohol only users differed in eight regions. The
data suggest subtle white-matter-tissue microstructural abnormalities reflecting poor tract coherence
and organization, but not tissue loss or demyelination, and imply interactive effects of cannabis and
alcohol or a possible neuroprotective role of cannabis
in binge drinking. In a further investigation of cognitive function in relation to white matter integrity, these
same authors found that reduced white matter integrity in temporal regions in cannabis and alcohol using

adolescents was associated with poor performance in
attention, working memory and speed of processing
tasks (Bava et al., 2010). Higher integrity of white matter fiber tracts in the cannabis users relative to controls
(interpreted as a neurodevelopmental compensatory
mechanism in response to exposure to cannabis) was
associated with better performance, except for in one
anterior region where higher integrity was associated
with poorer contextual verbal memory performance.
The interactive effects of cannabis and alcohol should
be further investigated, particularly as they are frequently used together by adolescents.
Altered cortical gyrification in the frontal lobe
and abnormal age-related changes to gyrification and
cortical thickness have also recently been reported in
adolescent and young adult users (Mata et al., 2010).
Cannabis users showed bilaterally decreased concavity
of the sulci (i.e. greater flattening) in frontal, temporal
and parietal lobes, and thinner sulci in the right frontal
lobe, in the absence of global brain structural differences
between users and controls. Abnormal cortical gyrification may reflect abnormal neurodevelopment or neurodegeneration. A lack of normal association between
these measures and increasing age in the cannabis users,
together with a lack of observed associations with specific cannabis-use parameters led the authors to speculate that cannabis use during adolescence or young
adulthood might prematurely alter cortical gyrification
toward patterns usually seen at a later age.
Further specific investigations of brain structure
and function are clearly warranted in adolescent cannabis-using samples to verify whether cannabis has
specific and/or more detrimental effects than in adult
users; whether there are age-of-onset-dependent and
gender effects; and whether there is a progression of
brain morphological abnormalities with continued
cannabis use, or reversal with abstinence.

Patients with psychosis
Since brain structural changes are evident in patients
with schizophrenia, and there is mounting evidence for
similar changes in association with heavy cannabis use,
it is possible that cannabis may exert greater adverse
effects on brain morphology when the brain is already
compromised. Indeed, this is most likely to occur in
brain regions known to be altered in both heavy cannabis users and patients with schizophrenia (e.g., hippocampus). In line with this, a number of recent studies
have investigated brain morphology in patients with
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schizophrenia or early psychosis and comorbid cannabis use.
No differences in brain structure between patients
with established schizophrenia who did and did not
use cannabis were reported by Cahn et al. (2004), while
Potvin et al. (2007) found increased striatal grey matter densities in schizophrenia patients with comorbid
substance-use disorders (primarily cannabis). In
first-episode psychosis patients who use cannabis,
decreased grey matter volumes of the anterior cingulate (Szeszko et al., 2007), right posterior cingulate
cortex and left hippocampus (Bangalore et al., 2008)
were reported relative to their non-using counterparts
and to healthy controls. Trends toward smaller left and
right cerebellar volumes were also apparent (Bangalore
et al., 2008). Rais and colleagues (2008) reported
greater lateral and third ventricle enlargements and
more pronounced total cerebral grey matter volume
reduction over 5 years in first-episode schizophrenia
patients who used cannabis compared with those who
did not, as well as in comparison with healthy controls
(2.67% and 5.09% reduction, respectively). The results
were suggested to explain some of the detrimental
effects of cannabis use in patients with schizophrenia.
We have recently reported hippocampal shape alteration (Solowij et al., 2010) and an almost 30% loss of
cerebellar white matter relative to healthy controls
in patients with schizophrenia and extensive cannabis use histories (Solowij et al., 2011). Finally, Dekker
et al. (2010) found that the age of onset of cannabis
use (before age 15 years versus age 17 years or later)
had no bearing on white matter integrity of the corpus callosum in a sample of young adults with recent
onset schizophrenia, while cannabis-naïve patients
showed greater abnormalities. These results support
the notion that cannabis-using patients may represent
a group who developed psychosis in part at least as a
consequence of their cannabis use (Dekker et al., 2010;
Yücel et al., 2010). Clearly, the impact of cannabis use
on brain function and structure in schizophrenia also
warrants further investigation.

What might be the implications
of structural brain changes in
cannabis users?
It is often assumed that alterations in the morphology
of the brain may underlie impaired cognition and may
indicate neural substrates of risk for the development
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of psychosis, but there are limited data to support these
notions. The interrelationships between cognition and
psychopathology, and indeed between brain structure
and function, are complex.
Few structural brain imaging studies of cannabis users have specifically examined the relationship
between brain volumes and cognitive performance
measures and most of those that did found no associations (Tzilos et al., 2005; Jager et al., 2007; Medina
et al., 2007b; Yücel et al., 2008) or isolated relationships
(Medina et al., 2007a; Solowij et al., 2008). An exception
to this was the finding of poor white-matter structural
integrity being related to poorer cognitive performance in cannabis and alcohol-using adolescents (Bava
et al., 2010). The lack of association in most studies
might be interpreted as aberrant associations between
brain structure and function, as discussed elsewhere
(Solowij et al., 2009).
The growing literature reporting an association
between cannabis use and the development of psychopathology, including both psychotic and depressive
symptoms, has searched for mediators of risk such as
genes (eg. COMT; Caspi et al., 2005), but associations
between the development of psychotic or depressive
symptoms and brain changes in cannabis users have
not been rigorously investigated. We reported an association between smaller left hippocampal volume in
cannabis users and subclinical positive psychotic symptoms as measured by the Scale for the Assessment of
Positive Symptoms (SAPS) (Yücel et al., 2008). Positive
symptom scores were also correlated with cumulative
cannabis exposure. The cannabis users in our sample were carefully screened for DSM-IV Psychotic
Disorders, had never been diagnosed with Major
Depressive Disorder and had never sought treatment
for any psychological disorders. Yet the majority of the
sample endorsed beliefs (scores on the SAPS ranged
from Questionable to Mild) concerning ideas of persecution, reference, mind reading, sin and/or guilt,
while some displayed bizarre clothing/appearance or
reported bizarre social/sexual behavior. Smaller left
hippocampal volume was also significantly correlated
with higher scores on the paranoid subscale of the Brief
Symptom Inventory (BSI) (unpublished data). Negative
symptoms were elevated in the cannabis users but
were unrelated to hippocampal volumes. Depressive
symptoms, which were also elevated, did not correlate with volumetric measures of any brain region, and
the relationship between left hippocampal volume and
cumulative exposure to cannabis remained significant
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after controlling for depressive symptoms. An association between depression and hippocampal volume is
seen in the more persistent forms of Major Depressive
Disorder (eg. MacQueen et al., 2005; Lorenzetti et al.,
2009), which does not apply to our sample. One other
study has reported an association between overall brain
white-matter volume and depressive symptoms in adolescent/young adult cannabis users without diagnosable mood disorders (Medina et al., 2007b).
Subclinical positive psychotic symptom scores in
the heavy cannabis users of our sample correlated with
spatial span errors, but no other associations between
cognitive measures and symptoms were observed
(Solowij et al., 2008). Skosnik and colleagues (2001,
2006, 2008) have found associations between cognitive
(eg. poor negative priming) and psychophysiological
measures (e.g. P300 to affective stimuli; 20 Hz neural
synchrony), and higher scores on the Schizotypal
Personality Questionnaire, on which cannabis users
generally obtained high positive-syndrome scores.
Acute administration of THC to healthy volunteers
and patients with schizophrenia induces both cognitive
impairment and transient positive and negative symptoms (Chapter 18; D’Souza et al., 2004, 2005; Koethe
et al., 2006), and sensitivity to the psychosis-inducing
and cognitive-impairing effects of cannabis may be
genetically mediated (Chapter 12, Henquet et al., 2006).
In patients with schizophrenia, associations between
positive psychotic symptoms and memory deficits, and
volumetric measures of the hippocampus, the superior
temporal gyrus, and the temporal lobe in general, have
been demonstrated, as well as between negative symptoms, executive function and prefrontal cortical measures (Antonova et al., 2005; Gur et al., 2007; Nestor
et al., 2007; Hurlemann et al., 2008) and in particular,
in relation to white matter structural integrity (Szeszko
et al., 2008). This suggests that further investigation of
brain structural changes in cannabis users, in relation
to symptoms and cognition, is warranted.
A crucial question is the extent to which interrelated structural-functional aberrations involving
the hippocampus, prefrontal regions or indeed other
brain structures in cannabis users, might reflect a vulnerability to schizophrenia. Our own findings suggest
that long-term exposure to cannabis constitutes a vulnerability to psychopathology by disrupting the structural integrity of brain regions that are also involved
in psychotic (and affective) disorders. We propose
that long-term heavy cannabis use leads to structural
brain changes and associated deleterious functional

(cognitive and mental health) sequelae that resemble
aspects of schizophrenia. These changes may occur not
only in individuals who are vulnerable to the development of such disorders, but also in nonvulnerable
individuals if cannabis is used heavily for prolonged
periods or commences during crucial neurodevelopment periods such as early adolescence.

Conclusions
Strong evidence for cumulative, sometimes doserelated, neuronal damage or microstructural alterations following chronic exposure to cannabinoids
(largely THC) comes from the animal literature. While
previous research failed to identify structural brain
abnormalities in human cannabis users, more recent
studies using high-resolution imaging techniques,
combined with more robust delineations of specific brain regions in very heavy cannabis users, have
revealed evidence of dose-related alterations, mostly in
the hippocampal and parahippocampal regions. Our
own findings of significant hippocampal and amygdala
volume loss in cannabis users suggest potential toxicity
due to cumulative exposure to large doses of cannabis
over many years. However, the structural neuroimaging studies of cannabis users have so far focused on a
narrow range of brain regions. Cannabis use, particularly during early adolescence, may affect the morphology of other cortical (e.g. PFC) and subcortical (e.g.
striatum) brain areas, where cannabinoid receptors are
heavily concentrated. Hippocampal changes accord
with hippocampal functional alterations in functional
imaging studies, which together with evidence of aberrations from spectroscopic and DTI studies, implicate the PFC. Evidence for damage to white-matter
integrity in cannabis users implicates neural circuitry
across multiple regions. Differences in the methods of
measurement used and the brain regions investigated
and small sample sizes of varying age and exposure to
cannabis, may have contributed to the heterogeneity of
findings across human studies overall.
While the evidence is only beginning to accumulate from a small number of studies that have used
rigorous methods to investigate structural brain alterations in cannabis users, it seems that long-term heavy
cannabis use can result in brain pathophysiological
and functional changes that resemble aspects of
schizophrenia. The data suggest that such alterations
are likely to occur when cannabis is used very heavily
over a prolonged period and typically involve medial
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temporal lobe structures. The cumulative evidence
for neurocognitive dysfunction similar to that seen
in schizophrenia and the development of subclinical
psychotic symptoms in cannabis users, combines with
the limited data from structural neuroimaging studies to support our proposition that chronic cannabis
use may result in schizophrenia-like changes in brain
structure and function. This is further supported by
evidence that long-term exposure to cannabis may
result in lasting dysfunction of the endogenous cannabinoid system, as well as alterations in the functionality of a number of neurotransmitter systems – changes
that resemble schizophrenia-like conditions in the
brain (see Solowij et al., 2009). There may be multiple moderators or mediators of adverse sequelae
from long-term heavy cannabis use, including genetic variation, gender, environmental factors and early
neurodevelopmental insults and stress, that interact
with cumulative exposure to high-dose cannabis use
to produce schizophrenia-like sequelae. A crucial factor is in determining the parameters of cannabis use
that lead to these structural and functional alterations
in individuals who are, compared with those who are
not, at high risk for the development of neuropsychiatric disorders, at various neurodevelopmental periods, and identifying the protective mechanisms that
prevent the onset of such potentially devastating
disorders.
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